We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study With Arctic Root Compared With the Extract When Combined With Schizandra and Russian Root (Adapt 232), Standardized Ginseng Extract and Placebo Regarding Impact on the Level of Energy, Ability to Work Under Stress, Quality of Life and Wellbeing, in Middleaged Women Who Are Still Employed

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01006460
First Posted: November 2, 2009
Last Update Posted: August 27, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Frederiksberg University Hospital
  Purpose
This is clinical trial to document the efficacy of a proprietary standardized extract of Arctic root in comparison to a standardized commercial extract of ginseng and placebo from an every day consumer perspective to ameliorate mild depression, reduce stress and improve quality of life. A newly developed adaptogenic formulation, Adapt 232, was included into the study in order to evaluate its effect in comparison to the others.

Condition Intervention
Depression Stress Drug: Rhodiola rosea, L Drug: Rhodiola rosea, L., Eleutherococcus senticosus, Schisandra chinensis Drug: Panax ginseng Drug: Placebo - dark brown sugar

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo Controlled, Parallel, Double Blinded Trial With Rhodiola Rosea Extract SHR-5 (Arctic Root) Compared With the Extract When Combined With Schizandra and Russian Root (Adapt 232), Standardized Ginseng Extract and Placebo Regarding Impact on the Level of Energy, Ability to Work Under Stress, Quality of Life and Wellbeing, in Middleaged Women Who Are Still Employed

Further study details as provided by Frederiksberg University Hospital:

Primary Outcome Measures:
  • Psychological parameters: changes in cognitive functions as measured by the D2 Test of Attention [ Time Frame: Over a period of 28 days of treatment ]

Secondary Outcome Measures:
  • Depression parameters: changes in depressive state as measured by the using Hamilton Depression Rating Scale (HAM-D) and Bechs Depression Inventory (BDI). [ Time Frame: over a period of 28 days of treatment ]
  • Quality of Life parameters: changes in quality of life as measured by the SF-36 scale, Danish Stress Profile (SP) test and questions regarding various aspects of well-being as formulated in a non-validated VAS scale [ Time Frame: Over a period of 28 days of treatment ]

Estimated Enrollment: 200
Study Start Date: November 2009
Study Completion Date: August 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Adapt 232 Drug: Rhodiola rosea, L., Eleutherococcus senticosus, Schisandra chinensis
3 capsules twice a day
Experimental: Arctic root group Drug: Rhodiola rosea, L
3 Capsules twice a day
Active Comparator: Ginseng group Drug: Panax ginseng
3 capsules twice a day
Placebo Comparator: Placebo group Drug: Placebo - dark brown sugar
3 capsules twice a day

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • healthy females, over 40 years of age, who have stated that they for a longer period of time have felt stressed due to demanding daily activities at work and/or at home.

Exclusion Criteria:

  • suffering from any known medical disease, e.g. cardiovascular, joint, and liver or kidney diseases, cancer, or psychiatric disease.
  • with a psychiatric diagnose, using narcotics or suffering from HIV.
  • with known allergy to any of the study medications.
  • misusing euphorizing or pain killing drugs
  • having used any adaptogenic product the last 2 months.
  • having used cortisol or any other corticosteroid products the last 6 months
  • being pregnant or breast-feeding
  • which at the first interview are judged to be not cooperative or not to be able to finalize the study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01006460


Locations
Denmark
Department of Clinical Biochemistry, Frederikbergs Hospital
Frederiksberg, Denmark, 2000
Sponsors and Collaborators
Frederiksberg University Hospital
Investigators
Principal Investigator: Kaj Winther, Dr Clinical Biochemistry department, Frederiksberg Hospital
  More Information

Responsible Party: Kaj Winther Hansen, Frederiksbegg University Hospital
ClinicalTrials.gov Identifier: NCT01006460     History of Changes
Other Study ID Numbers: SHR5/DK
First Submitted: November 1, 2009
First Posted: November 2, 2009
Last Update Posted: August 27, 2010
Last Verified: November 2009

Keywords provided by Frederiksberg University Hospital:
Quality of life and subjective well-being in middle aged women